Study of HBI0101 (NXC-201) CAR-T Therapy in Multiple Myeloma and Light-Chain Amyloidosis

This study is testing HBI0101 (also called NXC-201), a CAR-T cell therapy — where a patient's own immune cells are engineered in a lab to recognize and attack cancer cells — for people with multiple myeloma (a blood cancer) or light-chain amyloidosis (a protein buildup disease) that has relapsed or stopped responding to prior treatments. **You may be eligible if...** - You are 18 or older with confirmed multiple myeloma or light-chain amyloidosis - Your cancer has relapsed or is refractory (no longer responding) to previous treatments - You have received at least two prior treatment regimens, including drugs called proteasome inhibitors and immunomodulatory drugs (if you have myeloma) - You have measurable disease at the time of screening - Your organ function is adequate **You may NOT be eligible if...** - You have active, uncontrolled infection - You have a history of certain serious autoimmune diseases - You have received prior CAR-T therapy targeting the same cancer protein (BCMA) - You have active central nervous system involvement of your cancer - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.